863604-64-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3-fluoro-N-methoxy-N-methyl-4-nitrobenzamide is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure, which includes a fluorine atom, a methoxy group, and a methyl group, contributes to its potential biological activity, making it a valuable compound in the development of new drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-fluoro-N-methoxy-N-methyl-4-nitrobenzamide is employed as a building block for the design and synthesis of novel therapeutic agents. Its structural features allow for the fine-tuning of pharmacokinetic and pharmacodynamic properties, which is crucial for optimizing drug candidates.
Used in Chemical Synthesis:
3-fluoro-N-methoxy-N-methyl-4-nitrobenzamide is also used as a reagent in various chemical synthesis processes. Its versatility in forming different types of chemical bonds and its stability make it suitable for a range of applications in organic synthesis.

Upstream product

• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 157665-51-5 3-fluoro-4-nitrobenzoyl chloride 

Downstream Products

• 863604-65-3 N-[methoxy]-N-[methyl]-3-cyclopentylamino-4-nitrobenzamide 
• 1036725-95-7 C₁₅H₁₅N₃O₆ 
• 159390-15-5 4-amino-3-fluorobenzophenone 
• 160538-51-2 3-fluoro-4-nitro-benzaldehyde 

Relevant academic research and scientific papers

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that affects an estimated 1 in 50000 individuals worldwide. Until recently, prophylactic HAE treatment options were limited to injectables, a burdensome administration route that has driven the need for an oral treatment. A substantial body of evidence has shown that potent and selective plasma kallikrein inhibitors that block the generation of bradykinin represent a promising approach for the treatment of HAE. Berotralstat (BCX7353, discovered by BioCryst Pharmaceuticals using a structure-guided drug design strategy) is a synthetic plasma kallikrein inhibitor that is potent and highly selective over other structurally related serine proteases. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having successfully completed a Phase III clinical trial (meeting its primary end point) and recently receiving the U.S. Food and Drug Administration's approval for the prophylactic treatment of HAE attacks in patients 12 years and older.

Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)

Based on screening hit 1, a series of tricyclic quinoxalinones have been designed and evaluated for inhibition of PARP-1. Substitutions at the 7- and 8-positions of the quinoxalinone ring led to a number of compounds with good enzymatic and cellular poten

INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE

Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.

PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

KINASE INHIBITORS

ABSTRACT The present invention provides kinase inhibitors of Formula I: .